North East and North Cumbria
ICS Formulary
 
back
10 Musculoskeletal and joint diseases
10-02 Drugs used in neuromuscular disorders

Mexiletine Namuscla®
Formulary

  • Approved for the treatment of myotonia in patients with non-dystrophic myotonic disorders in line with NICE and NHSE commissioning policy (SSC2001). 


 
Link  NICE TA748: Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders

Red View adult BNF  View SPC online  View childrens BNF  HCD
Nusinersen Spinraza®
Formulary
  • 12mg solution for injection
  • Approved as an option for treating 5q spinal muscular atrophy (SMA) types 1, 2 or 3 in line with NICE.

 
Link  NHS England Urgent Clinical Commissioning Policy Statement (170018/P)
Link  NICE TA588: Nusinersen for treating spinal muscular atrophy

Red View adult BNF  View SPC online  View childrens BNF  HCD
Risdiplam Evrysdi®
Formulary
  • 0.75mg/1ml oral solution
  • Approved for treating spinal muscular atrophy in line with NICE
  • To be provided by Newcastle Hospitals homecare service only 
Link  NICE TA755: Risdiplam for treating spinal muscular atrophy

Red View adult BNF  View SPC online  View childrens BNF
Vamorolone Agamree®
Formulary
  • 40 mg/ml oral suspension
  • Approved for treating Duchenne muscular dystrophy in people 4 years and over in line with NICE
Link  NICE TA1031:Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over

Red View adult BNF  View SPC online  View childrens BNF  HCD
Efgartigimod alfa Vyvgart®
Non Formulary
  • Not recommended for treating antibody-positive generalised myasthenia gravis in line with NICE
Link  NICE TA1069: Efgartigimod for treating antibody-positive generalised myasthenia gravis

Not Recomended View adult BNF  View SPC online  View childrens BNF